Literature DB >> 24894748

A metoprolol-terbinafine combination induced bradycardia.

Emmanuel Bebawi1, Suhail S Jouni, Andrée-Anne Tessier, Anne Julie Frenette, Dave Brindamour, Maxime Doré.   

Abstract

To report a sinus bradycardia induced by metoprolol and terbinafine drug-drug interaction and its management. A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis. On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls. The electrocardiogram revealed a 37 beats/min sinus bradycardia. A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to bisoprolol and the heart rate remained normal. By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24894748     DOI: 10.1007/s13318-014-0205-x

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  27 in total

Review 1.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Authors:  Magnus Ingelman-Sundberg
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

Review 2.  Pharmacogenetics of beta-blockers.

Authors:  Jaekyu Shin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

3.  Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

Authors:  G Lefèvre; G Sedek; S S Jhee; M T Leibowitz; H-La Huang; A Enz; S Maton; L Ereshefsky; F Pommier; H Schmidli; S Appel-Dingemanse
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

4.  Nortriptyline intoxication induced by terbinafine.

Authors:  P H van der Kuy; P M Hooymans
Journal:  BMJ       Date:  1998-02-07

5.  Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.

Authors:  Norio Yasui-Furukori; Manabu Saito; Yoshimasa Inoue; Takenori Niioka; Yasushi Sato; Shoko Tsuchimine; Sunao Kaneko
Journal:  Eur J Clin Pharmacol       Date:  2006-11-24       Impact factor: 2.953

Review 6.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

7.  Stereoselective disposition of carvedilol is determined by CYP2D6.

Authors:  H H Zhou; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1995-05       Impact factor: 6.875

8.  Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.

Authors:  S K Jin; H J Chung; M W Chung; J-I Kim; J-H Kang; S W Woo; S Bang; S H Lee; H J Lee; J Roh
Journal:  J Clin Pharm Ther       Date:  2008-10       Impact factor: 2.512

9.  Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; Ping Li; Sudeep S Gill; Andreas Laupacis; David N Juurlink
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

10.  Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine.

Authors:  Young-Min Park
Journal:  Psychiatry Investig       Date:  2012-11-12       Impact factor: 2.505

View more
  2 in total

Review 1.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

Review 2.  Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions.

Authors:  Matthew P Rutman; John R Horn; Diane K Newman; Richard G Stefanacci
Journal:  Clin Drug Investig       Date:  2021-03-12       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.